These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. Spender LC; Hussell T; Openshaw PJ J Gen Virol; 1998 Jul; 79 ( Pt 7)():1751-8. PubMed ID: 9680139 [TBL] [Abstract][Full Text] [Related]
5. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. Elliott MB; Pryharski KS; Yu Q; Boutilier LA; Campeol N; Melville K; Laughlin TS; Gupta CK; Lerch RA; Randolph VB; LaPierre NA; Dack KM; Hancock GE J Virol; 2004 Aug; 78(16):8446-54. PubMed ID: 15280453 [TBL] [Abstract][Full Text] [Related]
6. Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. Krempl C; Murphy BR; Collins PL J Virol; 2002 Dec; 76(23):11931-42. PubMed ID: 12414935 [TBL] [Abstract][Full Text] [Related]
7. Recombinant vaccinia virus coexpressing the F protein of respiratory syncytial virus (RSV) and interleukin-4 (IL-4) does not inhibit the development of RSV-specific memory cytotoxic T lymphocytes, whereas priming is diminished in the presence of high levels of IL-2 or gamma interferon. Bembridge GP; Lopez JA; Cook R; Melero JA; Taylor G J Virol; 1998 May; 72(5):4080-7. PubMed ID: 9557697 [TBL] [Abstract][Full Text] [Related]
8. Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus. Hu B; Jiang J; Zhan J; Li G; Jiang Y; Guan X; Chen Y; Fang Z Virol J; 2014 Aug; 11():142. PubMed ID: 25107552 [TBL] [Abstract][Full Text] [Related]
9. The role of IFN in respiratory syncytial virus pathogenesis. Durbin JE; Johnson TR; Durbin RK; Mertz SE; Morotti RA; Peebles RS; Graham BS J Immunol; 2002 Mar; 168(6):2944-52. PubMed ID: 11884466 [TBL] [Abstract][Full Text] [Related]
10. Priming with a secreted form of the fusion protein of respiratory syncytial virus (RSV) promotes interleukin-4 (IL-4) and IL-5 production but not pulmonary eosinophilia following RSV challenge. Bembridge GP; Lopez JA; Bustos R; Melero JA; Cook R; Mason H; Taylor G J Virol; 1999 Dec; 73(12):10086-94. PubMed ID: 10559323 [TBL] [Abstract][Full Text] [Related]
11. Chimeric virus-like particles containing a conserved region of the G protein in combination with a single peptide of the M2 protein confer protection against respiratory syncytial virus infection. Qiao L; Zhang Y; Chai F; Tan Y; Huo C; Pan Z Antiviral Res; 2016 Jul; 131():131-40. PubMed ID: 27154395 [TBL] [Abstract][Full Text] [Related]
12. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus. Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914 [TBL] [Abstract][Full Text] [Related]
13. Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. Srikiatkhachorn A; Braciale TJ J Exp Med; 1997 Aug; 186(3):421-32. PubMed ID: 9236194 [TBL] [Abstract][Full Text] [Related]
14. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. Srikiatkhachorn A; Braciale TJ J Virol; 1997 Jan; 71(1):678-85. PubMed ID: 8985399 [TBL] [Abstract][Full Text] [Related]
15. Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Maher CF; Hussell T; Blair E; Ring CJ; Openshaw PJ Microbes Infect; 2004 Oct; 6(12):1049-55. PubMed ID: 15380773 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Safety and Immune Efficacy of Recombinant Human Respiratory Syncytial Virus Strain Long Live Attenuated Vaccine Candidates. Wang LN; Peng XL; Xu M; Zheng YB; Jiao YY; Yu JM; Fu YH; Zheng YP; Zhu WY; Dong ZJ; He JS Virol Sin; 2021 Aug; 36(4):706-720. PubMed ID: 33559831 [TBL] [Abstract][Full Text] [Related]
17. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Widjojoatmodjo MN; Boes J; van Bers M; van Remmerden Y; Roholl PJ; Luytjes W Virol J; 2010 Jun; 7():114. PubMed ID: 20525213 [TBL] [Abstract][Full Text] [Related]
18. Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. Kim KH; Lee YT; Hwang HS; Kwon YM; Kim MC; Ko EJ; Lee JS; Lee Y; Kang SM J Virol; 2015 Nov; 89(22):11692-705. PubMed ID: 26355098 [TBL] [Abstract][Full Text] [Related]